1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Kissei Pharmaceutical Co., Ltd.

Kissei Pharmaceutical Co., Ltd.

3,815.00
JPY
0.00
(0.00%)
192.75BMarket Cap
Nov 04Next Earn
Kissei Pharmaceutical Co., Ltd.
TSE:4547
(Tokyo Stock Exchange)

Recent

price

3,815.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
1,186.33
1,238.47
1,214.14
1,367.76
1,390.73
1,457.21
1,473.24
1,540.02
1,547.69
1,353.82
1,479.54
1,417.78
1,463.56
1,670.12
2,025
2,343.62
- -
Revenue per Share
73.77
91.33
97.51
176.66
142.13
166.88
158.73
188.24
117.33
60.3
113.25
280.19
228.3
246.61
274.21
331.53
- -
Basic EPS, GAAP
49.32
58.79
143.85
191.12
85.34
71.17
80.31
139.96
107.31
270.4
-86.29
-8.37
-200.06
-77.56
34.18
-171.33
- -
Free Cash Flow per Basic Share
33
35.41
36.99
38.99
41.86
42.98
45.22
47.24
49
50.99
53.04
54.99
67.98
82.25
87.14
116.48
- -
Dividend per Share
2,280.02
2,393.13
2,614.19
2,770.27
3,074.63
3,226.32
3,258.74
3,760.95
3,901.39
4,119.86
4,755.68
4,366.88
4,204.63
4,977.38
4,882.67
5,552.08
5,552.08
Book Value per Share
2,254.63
2,374.62
2,598.3
2,756.82
3,058.58
3,209.7
3,220.55
3,724.22
3,868.88
4,087.51
4,720.12
4,332.86
4,171.95
4,932.32
4,838.42
5,504.58
5,504.58
Tangible Book Value per Share
54
52
51
51
50
49
49
48
47
47
47
46
46
45
44
42
42
Basic Weighted Avg Shares
64,387
64,669
62,494
70,400
70,108
71,297
71,707
73,998
72,302
63,245
69,044
65,381
67,493
75,579
88,330
97,406
- -
Sales/Revenue/Turnover
10.04
11.54
12.42
17.47
11.89
14.41
11.84
13.36
8.58
2.94
2.18
-2.14
-1.67
5.31
6.54
-3
- -
Operating Margin (%)
2,809
2,635
2,390
2,190
2,203
2,343
2,370
2,492
2,607
2,562
3,148
3,730
4,109
4,254
4,615
4,644
- -
Depreciation Expense
4,004
4,769
5,019
9,093
7,165
8,165
7,726
9,045
5,481
2,817
5,285
12,921
10,528
11,160
11,961
13,779
- -
Net Income, GAAP
36.69
40.72
36.91
31.96
31.31
26.4
23.24
22.21
22.27
37.6
28.06
21.05
22.27
21.86
23.28
17.35
- -
Effective Tax Rate (%)
6.22
7.37
8.03
12.92
10.22
11.45
10.77
12.22
7.58
4.45
7.65
19.76
15.6
14.77
13.54
14.15
- -
Profit Margin (%)
73,944
72,126
76,685
83,015
78,427
80,443
81,562
80,715
81,981
79,653
74,720
80,598
85,684
86,888
90,402
93,281
93,281
Working Capital
1,768
1,547
1,525
1,409
1,463
1,488
1,656
1,876
1,930
13
- -
- -
- -
- -
- -
- -
- -
LT Debt
123,932
123,384
134,783
142,820
150,718
158,123
157,782
176,091
182,706
192,968
219,952
202,178
194,813
221,134
210,125
231,535
231,535
Total Equity
3.16
3.43
3.64
5.78
3.76
4.75
4.01
4.47
2.61
0.61
0.52
-0.51
-0.43
1.49
2.02
-1.07
- -
Return on Invested Capital (%)
3.16
3.75
3.79
6.4
4.77
5.17
4.78
5.29
2.97
1.45
2.5
6.03
5.22
5.28
5.51
6.13
- -
Return on Capital (%)
3.23
3.86
3.89
6.56
4.89
5.3
4.9
5.43
3.06
1.5
2.57
6.14
5.33
5.39
5.58
6.28
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
ST Debt
- -
1,270
1,250
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
41
41
41
Market Capitalization
167,194
178,246
192,752

Working Capital

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
Total Current Assets
- -
119,876
114,969
Cash, Cash Equivalents & STI
- -
61,698
54,424
Accounts Receivable, Net
- -
28,344
30,761
Inventories
- -
26,241
25,521
Total Current Liabilities
- -
33,575
21,688
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,270
1,250
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.17%
1.4%
10.19%
Free Cash Flow
149.67%
283.54%
-577.6%
Net Income, GAAP
16.56%
30.87%
15.2%
Sales/Revenue/Turnover
3.52%
7.41%
10.28%
Total Cash Common Dividend
9.09%
14.86%
27.36%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19,313
17,665
20,881
17,720
75,579
2025
- -
- -
- -
- -
88,330
2026
- -
- -
- -
- -
97,406

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
70.95
52.67
59.17
63.8
246.61
2025
- -
- -
- -
- -
274.21
2026
- -
- -
- -
- -
331.53

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
82.25
2025
- -
- -
- -
- -
87.14
2026
- -
- -
- -
- -
116.48
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures and markets pharmaceutical products and therapeutic and care foods primarily in Japan. The company offers Calogra (Kalogra) tablets for ulcerative colitis; Tabuneos capsules for microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets and other desmopressin formulations for diabetes insipidus; Malizeb tablets; Tavaris (Tavalisse) tablets for chronic idiopathic thrombocytopenic purpura; Beova tablets for overactive bladder; Darbepoetin Alfa BS injection for renal anemia; Silodosin for benign prostatic hyperplasia-associated dysuria; and Fostamatinib, a tyrosine kinase inhibitor; along with protein-controlled and energy-supply nutritional foods. Kissei operates through pharmaceutical and other segments including system development, information processing, construction contracting and facility management services, with manufacturing plants in Matsumoto and Shiojiri, Nagano, research laboratories in Azumino, Nagano and Joetsu, Niigata, 10 sales branches and 42 sales offices across Japan, and an overseas subsidiary Kissei America, Inc. in the United States. Founded in 1946 and headquartered in Matsumoto, Nagano, the company maintains a Tokyo head office in Bunkyo-ku and focuses on urology, immunology, oncology and other therapeutic areas. Recent developments include a July 2025 licensing agreement with Viridian Therapeutics for veligrotug and VRDN-003 in thyroid eye disease treatment in Japan, securing $70 million upfront and up to $315 million in milestones; October 2025 approvals and licensing for Linzagolix in Taiwan and Canada for uterine fibroids and endometriosis; July 2025 launch of Tavalisse in South Korea; January 2025 sub-licensing of Tavalisse to Tai Tien in Taiwan and marketing authorization in South Korea; initiation of phase III trials for Linzagolix in endometriosis and Rovatirelin for spinocerebellar degeneration; opening of a Boston open innovation office in April 2025; and revisions to its five-year medium-term management plan "Beyond 80" in May 2025.